Call for Abstract

12th World Congress on Virology, will be organized around the theme “Viral infection ,Disease manifestation control and impact on Species”

Virology 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Virology 2017

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

The Americas commanded the most sizably voluminous share 42% of the Ecumenical Microbiology Market at an estimated $1485.02 million in 2013 and are expected to reach $1932.8 million by 2018, at a CAGR of 5.6% from 2013 to 2018.

Viral infections is one of the major cause of human and animal disease. Virus genomes are very small and they are incredibly diverse and subject to rapid genetic change. Viruses have their own ways of transmission. The mobility of animals increases the mechanisms of viral transmittance that have evolved, whereas plants remain immobile and thus viruses must rely on environmental factors to be transmitted between hosts.

  • Track 1-1Viral Genomics and Proteomics
  • Track 1-2Viral Tropism and Transmission
  • Track 1-3Cellular Factors Affecting Viral Replication and Pathogenicity
  • Track 1-4Viral Replication Cycle

Clinical Trial Management System (CTMS) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019", states that the worldwide clinical trial administration frameworks advertise, which was worth US$844 million in 2013, will develop at a CAGR of 14% somewhere around 2013 and 2019 to get total assets of an expected US$1,848.5 million by 2019.

Viral pathogenesis is the investigation of how organic infections cause ailments in their objective hosts, usually carried out at the cellular or molecular level. Vector-borne diseases are contaminations transmitted by the chomp of tainted arthropod species, for example, mosquitoes, ticks, sandflies, blackflies, etc. A blood-borne disease is one that can be spread through sullying by blood and other body liquids. RNA quieting controls quality expression to direct improvement, genome solidness and uneasiness impelled responses. In plants, RNA hushing is likewise perceived as a noteworthy safe framework focused against plant viruses.

  • Track 2-1Mechanisms of Viral Pathogenesis
  • Track 2-2Virulence Factors
  • Track 2-3Mechanisms of action in Viral Latency

Clinical Trial Management System (CTMS) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019", states that the worldwide clinical trial administration frameworks advertise, which was worth US$844 million in 2013, will develop at a CAGR of 14% somewhere around 2013 and 2019 to get total assets of an expected US$1,848.5 million by 2019.

Viral pathogenesis is the investigation of how organic infections cause ailments in their objective hosts, usually carried out at the cellular or molecular level. Vector-borne diseases are contaminations transmitted by the chomp of tainted arthropod species, for example, mosquitoes, ticks, sandflies, blackflies, etc. A blood-borne disease is one that can be spread through sullying by blood and other body liquids. RNA quieting controls quality expression to direct improvement, genome solidness and uneasiness impelled responses. In plants, RNA hushing is likewise perceived as a noteworthy safe framework focused against plant viruses.

  • Track 3-1Alpha Virus & Rubiviruses
  • Track 3-2Simian virus 40
  • Track 3-3Human Herpes virus and cancers
  • Track 3-4HPV associated cervical cancers
  • Track 3-5Hepatocellular carcinomas
  • Track 3-6Viral Gastroenteritis
  • Track 3-7Herpes Viruses,Pox Viruses & Picorna Viruses
  • Track 3-8Filoviruses- Ebola Virus, Westnile Viruses & Othomixovirus
  • Track 3-9Severe acute respiratory syndrome
  • Track 3-10Ebola Virus

The agricultural inoculants market, in terms of value is anticipated to reach $398.56 million by 2019, at a CAGR of around 9.5% from 2014.

The epidemiology of plant virus diseases concerns the cyclical development of virus diseases within plant populations in time and space. Tobacco mosaic virus (TMV) is a positive-sense single stranded RNA virus that infects a wide range of plants, especially tobacco and other members of the family Solanaceae. Mycology is the branch of science which deals with the study of fungi, including their genetic and biochemical properties, their taxonomy and their use to humans as a source for tinder, medicine, wine and entheogens, as well as their dangers, such as poisoning or infection.

  • Track 4-1Plant virus epidemiology, ecology and evolution
  • Track 4-2Viral vector biology and transmission
  • Track 4-3Wheat and rice viruses
  • Track 4-4Vegetable viruses
  • Track 4-5Tobacco virus
  • Track 4-6Grape wine leaf roll disease
  • Track 4-7Virus resistant plants and disease control
  • Track 4-8Plants virus-vector interactions
  • Track 4-9Mycology

Ebola virus disease(EVD), otherwise called Ebola hemorrhagic fever (EHF) or just Ebola, is a viral hemorrhagic fever of humans and different primates brought on by ebola infections. Signs and indications ordinarily begin between two days and three weeks in the wake of getting the infection with a fever, sore throat, solid torment, and cerebral pains. The infection spreads by direct contact with body liquids, for example, blood, of a contaminated human or different creatures

  • Track 5-1Zaire Ebola virus
  • Track 5-2Vaccination for Ebola Virus
  • Track 5-3Evolution on Ebola Virus
  • Track 5-4Epidemiology and surveillance

Viral diseases is a standout amongst the most principal dangers in aquaculture as a result of late technologic propels and increasing ability in the aquatic veterinary field. Whether the virus is viewed as endemic or outlandish. When all is said in done, no affirmed or effectual medications subsist for viral diseases in aquaculture species. Channel catfish infection (CCV) malady is an intense, destructive herpesvirus disease of broil and fingerling channel catfish that can bring about mortality of >80% at dihydrogen monoxide temperatures ≥25°C in modest fish (≤5 cm). No proficient treatment or immunizations subsist for these maladies and their control is consequently by hindrance of exordium and annihilation by stamping-out if there should arise an occurrence of sicknesses episode. Because of close contact with dodging dihydrogen monoxide the between reliance amongst wild and cultivated fish and between individual fish cultivates the study of disease transmission in aquaculture is burdensome. The monstrous greater part of fish infections are limited to fish and represent no danger to handlers or shoppers.

  • Track 6-1Koi Herpes Virus and Largemouth Bass Virus
  • Track 6-2Viral Nervous Necrosis (Betanodaviruses) and Salmonid Alphaviruses
  • Track 6-3Infectious Pancreatic Necrosis and Infectious Salmon Anaemia
  • Track 6-4Channel Catfish Virus Disease and Epizootic Hematopoietic Necrosis

The global animal healthcare market was esteemed at USD 27,861.2 million in 2013 and is expected to grow at a CAGR of 7.1% from 2014 to 2019, to achieve an expected estimation of USD 41,929.1 million in 2019.

Veterinary virology is the study of viruses in animals. It is an important branch of veterinary medicine. An emerging virus is a term applied to a newly discovered virus, one that is increasing in incidence or with the potential to increase in incidence. Zoonotic diseases/infections are those which can be naturally transmissible from vertebrate animals to humans. Prion disease represents a group of conditions that affect the nervous system in humans and animals.

  • Track 7-1Viral Molecular Diagnosis, Immunology and Vaccines development
  • Track 7-2Host-Virus Interactions and Pathogenesis and Prion Disease
  • Track 7-3Emerging Viruses and Zoonosis Epidemiology

The global infectious immunology market is forecast to reach $8.8 billion by 2017, growing at a compound annual growth rate (CAGR) of 6% during the period 2010-2017. The hepatitis infections fragment developed at 7% and was esteemed at $2 billion in 2010.

Cell signaling is part of a complex system of communication that administers basic cellular activities and coordinates cell activities. A Neutralizing antibody is an antibody which safeguards a cell from an antigen or infectious body by inhibiting or neutralizing any effect it has biologically. Cell-mediated immunity is an immune response that does not involve antibodies, but rather involves the activation of phagocytes, antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen.

  • Track 8-1Viral immune evasion
  • Track 8-2Receptors and signaling
  • Track 8-3Neutralizing antibodies
  • Track 8-4Adjuvants and cell-based immunity
  • Track 8-5Prophylactic and therapeutic vaccines

Due to the widespread infection of HCV and demand for these enhanced treatments, multiple estimates forecast the global market for HCV treatment will reach $20 billion yearly before the decade's get over.

Hepatitis is a medical condition defined by the inflammation of the liver and characterized by the presence of inflammatory cells in the tissue of the organ. Hepatitis A is an intense irresistible infection of the liver caused by the hepatitis A virus. Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) which affects the liver. It can cause both intense and chronic infections. HCV is spread primarily by blood-to-blood contact connected with intravenous drug use, inadequately cleaned therapeutic gear, and transfusions.

  • Track 9-1Hepatitis A
  • Track 9-2Hepatitis B
  • Track 9-3Hepatitis C
  • Track 9-4Hepatitis D
  • Track 9-5Hepatitis E
  • Track 9-6Epidemiology hepatitis
  • Track 9-7Hepatitis virology and immunology

The global HIV/AIDS market, including branded products and generics, was esteemed at $11.3 billion in 2010. This market is expected to reach $11.8 billion in 2011 and increase at a 4.6% compound annual growth rate (CAGR) over the 2011-2016 estimate period to reach $14.1 billion in 2016.

The human immunodeficiency virus is a lentivirus that causes HIV infection and AIDS.HIV diagnosis is done by testing your blood or saliva for antibodies to the virus. HIV/AIDS clinical trials are research studies done to have a better approach, distinguish, or treat HIV/AIDS. Clinical trials are the fastest way to determine if new medical approaches to HIV/AIDS are safe and effective in people.

  • Track 10-1Systems biology in HIV, METH and cART
  • Track 10-2HIV diagnosis
  • Track 10-3HIV and retroviral transmission and prevention
  • Track 10-4Anti-retroviral therapies and associated complications
  • Track 10-5Psychological and social issues associated with HIV
  • Track 10-6Opportunistic diseases in HIV
  • Track 10-7Immunology of HIV and retroviral infections
  • Track 10-8Clinical trials in HIV AIDS
  • Track 10-9HIV vaccines and advances
  • Track 11-1Sexual and Gender Minority Health
  • Track 11-2Gender-blending and fluid identities
  • Track 11-3HIV, STD and Hepatitis Testing Resources

The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%.

Significant point driving development of vaccine technology market join rising pervasiveness of contaminations, expanding government exercises for developing immunization over the globe, growing association interests in inoculation change, and rising exercises by non-government relationship for immunizations. Clinical trials are research concentrates that examine whether a therapeutic strategy, treatment, or gadget is safe and effective for people.

  • Track 12-1Virus Safety Risk Assessment
  • Track 12-2Virus Clearance Technologies
  • Track 12-3Optimizing Pre-clinical & Clinical Trials Performance
  • Track 12-4Future Potential of the Vaccine Market
  • Track 12-5Latest Developments in the Prophylactic and the Therapeutic Segment

The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. Major factors driving growth of vaccine technology market include rising prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. The global market for cancer vaccines is expected to grow to $4.3 billion by 2019, with a five-year compound annual growth rate (CAGR) of 1.3%

It gives an overview of nonhuman primate models of restoratively vital viral disease and also characteristic contaminations of nonhuman primates with human and animal viruses. This subject incorporates primate models of medicinally imperative viral diseases, for example, AIDS, theories on the beginnings of plague types of HIV, and viral illnesses brought on by non-simian infections in both wild and hostage primates.

  • Track 13-1Applications of viral vectors
  • Track 13-2Advances in antiviral vaccine development
  • Track 13-3Types of Vaccines
  • Track 13-4Vectors in Gene Therapy

Viral diseases/infections of the oral cavity, oral mucosa and perioral regions are generally encountered by dentists and have not received the required recognition until recently and viruses are both - ulcer genic and the tumorigenic agents of human oral cavity. The plethora of mammalian viruses in the lesions seen in periodontitis proposes that viruses play a significant role in oral diseases than earlier recognized. One of the most crucial target of oral microbiology in future would be to arbitrate the diversity, magnitude, frequency, pathogenicity, treatment and prognosis of oral viruses and the infections they cause.

  • Track 14-1Types of Oral Infections
  • Track 14-2Differential diagnosis of viral Oral infections
  • Track 14-3Oral infection by herpes simplex Virus
  • Track 14-4Oral infections by cytomegalovirus
  • Track 14-5Oral infection by Wart- HPV ( Human papillomavirus )
  • Track 14-6Oral infections by Coxsackie virus (cox)
  • Track 14-7Oral infections by Measles , Mums and Rubella virus ( MMR )

The Americas commanded the largest share 42% of the Global Microbiology Market at an estimated $1485.02 million in 2013 and are expected to reach $1932.8 million by 2018, at a CAGR of 5.6% from 2013 to 2018.

DNA immunization is a novel method used to efficiently fortify humoral and cellular immune responses to protein antigens. Viral vaccines contain either inactivated viruses or constricted viruses .Inactive viral vaccines contain a virus, which have lost their ability to replicate and in order for it to bring about a response it contains more antigen than live immunizations. Allergy immunotherapy is a clinically documented efficacious treatment, which may considerably reduce the patient’s allergic symptoms and the need for traditional, symptom-relieving medication. Antiviral drugs are a class of medication utilized particularly for treating viral contaminations.

  • Track 15-1DNA vaccines
  • Track 15-2Interleukin immune therapy
  • Track 15-3Antibody therapy against viruses
  • Track 15-4Gene therapy for viral infections
  • Track 15-5Viral vaccines
  • Track 15-6Vaccine allergy

Clinical Trial Management System (CTMS) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019", states that the global clinical trial management systems market, which was worth US$844 million in 2013, will grow at a CAGR of 14% between 2013 and 2019 to acquire net worth of an estimated US$1,848.5 million by 2019.

Vector-borne diseases are infections transmitted by the bite of infected arthropod species, such as mosquitoes, ticks, sandflies, blackflies,etc. A blood-borne disease  is one that can be spread through contamination by blood and other body fluids. RNA silencing controls gene expression to regulate development, genome stability and anxiety incited reactions. In plants, RNA silencing is also recognized as a major immune system targeted against plant viruses.

  • Track 16-1Viral culture
  • Track 16-2Vector and Blood born Diseases & Molecular Diagnosis of CNS Viral Infections
  • Track 16-3Virus Propagation Isolation
  • Track 16-4Nucleic acid detection
  • Track 16-5Viral serology test

The worldwide business sector for drug discovery technologies and products reached $38.4 billion in 2011. It is expected to expand to $41.4 billion in 2012 and to $79.0 billion in 2017, a compound annual growth rate (CAGR) of 13.8% somewhere around 2012 and 2017. Another report by vision gain, an independent media company based in London, predicts that the world market for drug discovery outsourcing will reach $16.6 billion in 2015.

Drug-drug interactions happen when a drug interacts, or meddles, with another drug. change the way either of the drug demonstration in the body, or cause sudden reactions. The drug included can be doctor prescribed solutions, over-the-counter meds and even vitamins and normal items.

  • Track 17-1Virus Safety Risk Assessment
  • Track 17-2Virus Clearance Technologies to Address Current Needs in Bio-manufacturing Facility Control and Protection
  • Track 17-3Latest Developments in the Prophylactic and the Therapeutic Segment
  • Track 17-4Optimizing Pre-clinical & Clinical Trials Performance
  • Track 17-5Exploring the Future Potential of the Vaccine Market and Achieving Vaccine Manufacturing Excellence

The worldwide business sector for drug discovery technologies and products reached $38.4 billion in 2011. It is expected to expand to $41.4 billion in 2012 and to $79.0 billion in 2017, a compound annual growth rate (CAGR) of 13.8% somewhere around 2012 and 2017. Another report by vision gain, an independent media company based in London, predicts that the world market for drug discovery outsourcing will reach $16.6 billion in 2015.

Drug-drug interactions happen when a drug interacts, or meddles, with another drug. change the way either of the drug demonstration in the body, or cause sudden reactions. The drug included can be doctor prescribed solutions, over-the-counter meds and even vitamins and normal items.

  • Track 18-1Stem cell therapy for viral infections: promises and challenges
  • Track 18-2New strategies to combat flu viruses
  • Track 18-3Strain identification assays and rapid diagnostic testing for viral infections
  • Track 18-4Clinical virology

Viruses and viral diseases have been at the focuses of science, horticulture, and drug for centuries, and some of our most noteworthy difficulties and triumphs have included virology. Technological developments have prompted to a superior comprehension of progressing logical difficulties, for example, those posed by viruses.

  • Track 19-1Viral Genomes Research
  • Track 19-2Bioinformatics of Viruses